A Gladwyne biotech company with roots at Yale University is making waves in the life sciences sector, writes John George for the Philadelphia Business Journal.
Xanadu Bio raised $11 million in a private stock sale, according to filings with the Securities and Exchange Commission. The infusion follows a $12 million round in 2022 and positions the young firm to expand its next-generation nanoparticle delivery platform.
Xanadu Bio was founded in 2021 and relocated to Montgomery County in 2022. The company is developing what it calls PACE technology, a biodegradable and scalable system for delivering nucleic acids like DNA and RNA directly to targeted tissues. The company’s pipeline includes vaccines for influenza, Covid-19, and RSV, as well as therapies for tissue-specific diseases.
CEO and co-founder Dr. Bruce Turner said the company remains “a Yale spinout developing Yale technology,” though it now operates virtually with employees across the U.S. and Europe. Turner, a Gladwyne resident, emphasized that the company has not yet chosen a permanent office location.
The startup has also drawn high-profile partners. In January, Xanadu entered into an agreement with Johnson & Johnson to explore new drug candidates using the PACE platform.
Read more about the Xanadu Bio, Gladwyne’s new biotech company, in the Philadelphia Business Journal.
